Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Chordia Therapeutics Inc. ( (JP:190A) ).
Chordia Therapeutics reported no business revenue for the six months ended February 28, 2026, while narrowing its operating loss to ¥662 million from ¥996 million a year earlier and posting a net loss of ¥633 million, equal to a basic loss of ¥8.95 per share. Total assets slipped to ¥2.51 billion and equity to ¥2.31 billion, though the equity ratio stayed high at 91.8%, reflecting a largely equity-funded balance sheet.
The company maintained a zero-dividend policy for the current fiscal year and left its full-year forecast unchanged, projecting an operating loss of ¥2.01 billion and a net loss of ¥1.96 billion, or ¥28.41 per share. The increase in shares outstanding to 73.73 million underscores its continued dependence on capital markets to sustain oncology pipeline development amid ongoing losses, a typical profile for early-stage drug developers.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange that focuses on discovering and developing oncology therapeutics. Operating under Japanese GAAP, it remains in a pre-revenue, development-heavy phase, with its financial profile characterized by ongoing R&D investment and reliance on equity financing rather than operating cash flows.
Average Trading Volume: 2,001,658
Technical Sentiment Signal: Sell
Current Market Cap: Yen9.11B
Find detailed analytics on 190A stock on TipRanks’ Stock Analysis page.